|
Ana Stavljenić-Rukavina

5.1 Introduction
Hereditary kidney disorders represent significant
risk for the development of end stage renal desease (ESRD). Most of
them are recognized in childhood, or prenataly particularly those
phenotypicaly expressed as anomalies on ultrasound examination (US)
during pregnancy. They represent almost 50% of all fetal
malformations detected by US (1). Furthermore many of urinary tract
malformations are associated with renal dysplasia which leeds to
renal failure.
Recent advances in molecular genetics have made a
great impact on better understanding of underlying molecular
mechanisms in different kidney and urinary tract disorders found in
childhood or adults. Even some of clinical syndromes were not
recognized earlier as genetic one. In monogenic kidney diseases
gene mutations have been identified for Alport syndrome and thin
basement membrane disease, autosomal dominant polycystic kidney
disease, and tubular transporter disorders. There is evident
progress in studies of polygenic renal disorders as
glomerulopathies and diabetic nephropathy. The expanded knowledge
on renal physiology and pathophysiology by analyzing the phenotypes
caused by defected genes might gain to earlier diagnosis and
provide new diagnostic and prognostic tool. The global increasing
number of patients with ESRD urges the identification of molecular
pathways involved in renal pathophysiology in order to serve as
targets for either prevention or intervention. Molecular genetics
nowadays possess significant tools that can be used to identify
genes involved in renal disease including gene expression arrays,
linkage analysis and association studies.
5.2 Major monogenic kidney diseases
Alport syndrome is a hereditary progressive
nephropathy characterized by lamellation and splitting of
glomerular basement membrane (GBM) and associated with
sensorineural defect leading to hearing loss and ocular defects
(2). It is recognized in early childhood by the hematuria and later
progression to renal failure, predominantely in males before the
age of six. In 85% families it was confirmed X-linked dominant
inheritance. After years of recurrent or persistent hematuria,
renal insufficiency is noted to occur, usually in the third or
forth decade of life, occasionally before the age of twenty.
Nephrotic syndrome may occurs in 30 - 40% of patients. Hearing loss
is variable, ranging from complete deafness to high-frequency loss
detected by audiometric exam. Associated abnormalities may include
megalocornea, lenticlonus, spherophakia, myopia, retinitis
pigmentosa, and macrothrombocytopenia. In females, the disorder is
usually mild, with only microscopic hematuria, and does not
typically progress to renal failure. The disease occurs at a gene
frequency of 1/5000 and is transmitted in most families as X-linked
dominant trait (2). The variety of mutations in COL4A5 gene is
underlying cause (3) (Table 5.1.). The disease is closely connected
to other, thin membrane disease, which is associated with COL4A3
and COL4A4 gene, members of gene families responsible for type IV
collagen synthesis. Collagen type IV is a major component of
basement membranes and different mutations are underlying defect in
all Alport syndrome and related diseases.
The term thin-basement � membrane nephropathy
characterized by diffuse thining of GBM is often associated with
urinary abnormalities and correspond not to a single clinical
syndrome and should be differentiated from thickened GMB with split
lamina densa as most characteristic ultrastructural lesion in
Alport syndrome.
Table 5.1. Genes
involved in major kidney disorders
|
Kidney disorder or syndrome
|
Genes
|
Proteins/Products
|
|
Alport syndrome (X linked)
|
COL4A5
|
Type IV collagen α5 chain
|
|
Alport Syndrome (autosomal recessive)
|
COL4A3 or
OL4A4
|
Type IV collagen α3 chain
Type IV collagen α4 chain
|
|
Alport syndrome with leiomyomatosis (X linked)
|
COL4A5 and COL4A6
|
Type IV collagen α5 and α6 chain
|
|
Benign familial hematuria (autosomal dominant)
|
COL4A4
|
Type IV collagen α4 chain
|
|
Autosomal dominant polycystic kidney disease 1 (PKD1)
|
PKD1
|
Polycystin 1
|
|
Autosomal dominant polycystic kidney disease 2 (PKD2)
|
PKD2
|
Polycystin 2
|
|
Autosomal recessive PKD
|
PKD3
|
Polycystin ?
|
|
VonLippel-Lindau (VHL) disease
|
TSC/VHL
|
VHL protein
|
|
Nephrogenic diabetes insipidus (X- linked)
|
ADHRV2
|
Vasopresin receptor V2
|
|
Nephrogenic diabetes insipidus (autosomal recessive)
|
AQP2
|
Aquaporin 2
|
|
Familial hypocalcuric hypercalcemia
|
CASR
|
Ca 2+ sensing receptor
|
|
X- linked recessive nephrolithiasis
|
CLCN5
|
Cl- channel
|
|
X- linked recessive hypophosphatemic rickets
|
CLCN5
|
Cl- channel
|
|
Fabry disease (X- linked)
|
GLA
|
α-galactosidaseA (α-galA)
|
|
Juveline nephronophtysis
|
NPHP1
|
|
|
Steroid resistant nephrotic syndrome
|
NPHS2
|
podocin
|
The most prevalent hereditary kidney disease is
autosomal dominant polycystic kidney disease (APKD) (1/400- 1/1000)
individuals) caused by genetic changes of PKD1 gene located on
chromosome 16 encoding membrane protein polycystin.The expression
of PKD1 protein was licalized ti the tubular epithelium
(podocytes). Polycystin protein contain a large extracellular
adhesive component, a series of 13 membrane-spanning domains and at
the C terminus a cytoplasmatic tait. The pathophysiological
background of clinical symptoms is probably in the function of this
protein. Polycystin is responsible for maintaining of renal
epithelial differentiation and organization (4-6). Polycystin is
involved in the signal conveying. The signal normaly conveyed from
the polycystin legends in the extracellular space to the interior
of cell is dirupted by mutations in PKD1 which probably leads to
abnormal differentiation of tubular cells and cyst formation.
Furthermore it was shown that PKD1 gene in some patients is
contiguous to one of genes involved in other disease (TSC2 gene)
named tuberous sclerosis (7).
PKD2 gene is localized on chromosome 4 and PKD2
protein contain more restricted extracellular domain than PKD1 and
the structure is compatible with one ion channel4. PKD 2 protein
has six transmembrane spans but the N and C- terminal domains has
aminoacid similarity with PKD1 protein. It was suggested that PKD2
protein belong to family of voltage-activated calcium and sodium
channel and therefore it is speculated that both PKD1 and PKD2
proteins are involved in a common signal transduction pathway.
The clinical manifestations of APKD as pain,
bleeding, infection and stone have been known for decades. The most
frequent complication is progressive renal failure which leads to
end stege renal disease (ESRD) at age between 40-59. But the large
deletions disrupting both PKD1 and TSC2 gene are responsible for
early progression of APKD and ESRF in young children.
The determinants of progression are both genetic
and non-genetic (infections, comorbidity), the rate of progression
is slower in PKD2 families, in females than in males, in whites
than in black patients. Hypertension is an early complication
leading to ventricular hypertrophy. The earlier clinical
intervention might be of benefit for prevention of cardiovascular
complications. Potential complications are additionally liver
cysts, gastrointestinal manifestations, portal hypertension and
fatal intracranial aneurism rupture.
In comparison with autosomal dominant PKD where
cysts arise from any tubular segment in autosomal recessive PKD
(ARPKD) the renal cysts develop from collecting ducts. Beside renal
involvement congenital liver fibrosis and portal hypertension were
found in early life.
Further cystic disease complex include juvenile
nephronophthisis characterized by diffuse interstitial fibrosis
with thickened and multilayered tubular basement membranes. The
leading finding are medullar cysts. It is an autosomal recessive
disease caused by gene located on chromosome 2 (8, 9).
Beside APKD renal cysts sometimes may be found in
other patients suffering from tuberous sclerosis (TSC) and von
Hippel Lindau disease (VHL).
Nephrogenic diabates insipidus as congenital form
include X linked recessive and autosomal recessive types.The
various mutations of gene ADHRV2 that encodes V2 ADH receptor in
the collecting tubular cells (10). or heterozygous gene mutations
encoding aquaporin-2, a water channel in the collecting tubule (11,
12) are major genetic background. Clinical symptoms are
characterized by insensitivity of renal concentrating system to the
effects of antidiuretic hormone arginine vasopressin (ADH).
Other hereditary disorder of tubular transport
system is Liddle's syndromcaused by gene mutations encoding of β
and γ subunits of Na+ channels.
Hypocalcemic alkalosis associated with
hypocalcinuria and hypomagnesemia are biochemical characteristics
of other tubular transporter disorder named Gitelman
syndrome. Other three hereditary
disorders of hypercalciuric nephrolithiasis (X-linked recessive
nephrolithiasis, Dent' disease and X-linked phosphemic rickets) are
caused by mutations in the same CLCN5 gene which encodes kidney Cl-
channel (13). Laboratory findings are characterized by
low-molecular weight proteinuria and hypercalciuria. Those
disorders might participate in the pathogenesis of essential
hypertension. Some of these disorders are complicated with
nephrolithiasis. Cystinuria, autosomal recessive disorder, due to
defect in dibasic tubular reabsorption liads to stone formation,
Dent's disease and X-linked calcium nephrolithiasisare also
characterized by proximal tubular dysfunction .
Autosomal recessive Bartters syndrome is recently
characterized as mutation of gene encoding for
burnetanide/furosemide sensitive Na-K-2 C/co-transporter located in
the apical membrane of ascending limb of Henleys loop (14). The
inhibitory mutations of gene encoding for Na-Cl co-transporter
inhibited by thiezide are found and this explains why this syndrome
encompasses abnormalities reminiscent of long-term thiazide
administration as well as low blood pressure. In the contrary
activating mutations of these genes are accompanied with high blood
pressure. (Liddle's syndrom).
A number of inherited metabolic disorders have an
significant impact on kidney function. Most promiments metabolic
disorders with prominent glomerular involvment as Anderson-Fabry's
disease, lecitin-cholesterol acyl transferase (LCAT) deficiency,
genetic amyloidosis have been identified recently and diagnostic
methods improved by new technologies (PCR in real time,
microarray). Moreover the improvement of diagnostic methods for
prominent extraglomerular metabolic diseases with renal involvment
as for hyperoxaluria,uremic nephropathy,cysinosis, APRT deficiency
and mitochondrial cytopathies brings to clinicians new potentials
for earlier diagnosis and intervention as well.
5.3 Polygenic kidney disorders
The association between glomerulonephritis and
some genetic potential background were studied in recent years .An
insertion/deletion polymorphism in intron 16 of
angiotenzin-converting enzyme (ACE) gene studied in the number of
patients with glomerulonephritis as well as other chronic disorders
did not bring new data. The DD genotype on the contrary was found
to be associated with rapid progression in IgA nephropathy. In
addition IgA nephropathy patients with DD genotype respond to ACE
inhibition therapy with lisinopril for decresing proteinuria (15,
16).
The association studies concerning diabetic
nephropathy gave contradictory results. Several studies have found
an association between a trinuleotide repeats in exon 2 of the
CNDP1 gene which encodes carnosine and diabetic nephropathy
(17).
Renal injuries with monigenic cause represent a
small but significant fraction of the total spectrum of renal
diseases. The most common types of renal disoreders are the result
of complex interplay between multigenic and environmental
interplay. But there is no doubt that altered expression of genes
that are mutated in monogenic kidney damage are contributing to a
great extent to acquired renal damage. Further studies should
determine the nature of association between genetic and
environmental factors involved in renal injury and progression of
disease
5.4 The strategies for research of genes potentially involved in
kidney disease
The technologies developed for the Human Genome
Project, the recent surge of available DNA sequences resulting from
it and the increasing pace of gene discoveries and characterization
have all contributed to new technical platforms that have enhanced
the spectrum of disorders that can be diagnosed. The importance of
determining the disease-causing mutation or the informativeness of
linked genetic markers before embarking upon a DNA-based diagnosis
is, however, still emphasized.
Fluorescence in situ hybridization
(FISH) technologies provide increased resolution for the
elucidation of structural chromosome abnormalities that cannot be
resolved by more conventional cytogenetic analyses, including
microdeletion syndromes, cryptic or subtle duplications and
translocations, complex rearrangements involving many chromosomes,
and marker chromosomes (Figure 5.1. FISH technologies in molecular
cytogenetic studies).

Figure 5.1. FISH
technologies for molecular cytogenetic studies.
Interphase FISH and the quantitative
fluorescence polymerase chain reaction are efficient tools for
the rapid diagnosis of selected aneuploidies, the latter being
considered to be most cost-effective if analyses are performed on a
large scale.
Interphase and metaphase FISH, either as
a single probe analysis, or using multiple chromosome probes, can
give reliable results in different clinical situations. It should
be noted that there may be variation in probe signals both between
slides (depending on age, quality, etc. of metaphase spreads) and
within a slide. Where a deletion or a rearrangement is suspected,
the signal on the normal chromosome is the best control of
hybridisation efficiency and control probe additionaly provides an
internal control for the efficiency of the FISH procedure.
Depending on the sensitivity and specificity of
the probe and on the number of cells scored, the possibility of
mosaicism should be considered, and comments made where
appropriate. By using locus-specific probes at least 5 cells should
be scored to confirm or exclude an abnormality. In multiprobe
analysis: three cells per probe should be scored to confirm a
normal signal pattern. Where an abnormal pattern is detected,
confirmation is advisable.
More recently new method for fast identification
of chromosomal abnormalities has been developed as high resolution
array comparative genomic hybridization (aCGH) which provide
genome-wide analysis of chromosome copy number and structural
change.
DNA as analyte in genetic testing may be
isolated from different biological material as peripheral blood,
amnionic fluid, chorion villi, or maternal blood as free DNA.
Todays techniques for gene mutation analysis are in general
modification of polymerase chain reaction (PCR) technique where
small quantity of DNA �in vitro� is multiplicated by under the
activity of specific enzyme, the presence of primers and nucleotide
mixture. The quantity of DNA obtained �in vitro� allow further the
aplication of other analytical technologies for detection of
mutation, deletion or other changes. Single strand conformation
polymorphism (SSCP) method is used for detection of small mutations
of gene and still is the most convenient method for detection of
mutations of particular exons, as step before confirmation of
mutation by sequencing. PCR in real time combine PCR and automatic
multicolor fluorescence analysis of mutations and deletions allow
fast analysis of number of DNA samples (18).
Sequencing of DNA molecule allow determination of
subsequent nucleotide A(denin), T(imin), G(uanin) and C(itozin)
sequence. Multicolor, multichanell automatic sequencing with
fluorescence emission developed in last five years made this
procedure fast, efficient and safe.
The high throughput microarray technologies
combined with robotics are the newest development in molecular
genetic testing. The application of this technology and its
different modifications allowed to analyze whole gene or more genes
simultaneously which bring to clinicians new tool for rapid and
safe diagnostic procedures (18). The advances in automation of
analytical procedures and fast growing of test number bring to
analyst the need for broad external quality assessment by certified
proficiency testing bodies. In general, every laboratory which
delivers test results for prenatal care should be recognized by
certified referral laboratory for each test performed in this
laboratory.
Gene expression array is used for profile gene
expression. The advantage of this technique is that it enables
innovative study design such as integration with other techniques
and comparison between tissues or cell types (19).
Linkage analysis is recommended for
identification of a gene or genetic region that has large effect on
phenotype. It allows the causal relationship between genotype and
phenotype. The limitation is that it requires rare families for
evaluation of results (19).
The association analysis enables to identify
common susceptibility variants underlying the disease and is
suitable for study of complex diseases. Nevertheless it requires
large cohorts, higher costs and clinical significance of
association is unknown.
Genome-wide association study is recommended for
the study of genetic factors that influence common, complex
diseases with high throughput covering whole genome. The large
number of participants is needed for genes that have not very
strong influence.
Recommended literature:
- Pirson Y, Chaveau D, Grunfeld JF. Autosomal
dominant polycystic kidney disease. In Oxford Textbook of Clinical
Nephrology. Davison A.M. et aled., 2nd Ed 1997; Oxford
University Press.
- Gregory MC, Atkin CL. Alport Syndrome. In
Disease of the Kidney. Schrier RW and Guttschalk CW (8 ed.),
Little, Brown 1993;pp571.
- Tryggvason K. Mutations in type IV collagen
genes and Alpert phenotypes. Molecular pathophysiology and Genetics
of Alpert Syndrome. Contrib. Nephrol 1996;117:154.
- Saito A, Sakatsume M, Yamazaki H, Ogata F,
Arakawa M. A deletion mutation in the 3?end and of a5(IV) collagen
gene in juvenile-onset Alport syndrome. J.Am Soc Nephrol
1994;4:1649.
- Kawai S, Nomura S, Harano T,Fukushima T, Osawa
G. The Japanese Alport Network. The Col 4A5 gene in Japanese Alport
syndrome patients. Spectrum mutations of all exons. Kidney Int
1996;49:814.
- Ward CJ, Tirley H, Ong ACM, et al.
Polycystin, the polycystic kidney disease 1 protein is expressed by
epithelial cells in fetal, adult and polycystic kidney. Proc Natl
Acad Sci 1996.;93:1524.
- Brook-Carter PT, Peral B, Ward CJ, et
al. Deletion of the TSC2 and PKD1 genes associated with severe
infantile polycystic kidney disease: A continuous gene syndrome.
Nat Genet 1994;8:28-32.
- Konrad M, Saunier S, Heidet L, et al.
Large homozygous deletions of 2q13 region are the major cause of
juvenile nephronophtisis. Hum Mol Genet 1996;5:367-71.
- Antignac C, Arduy CH, Beckman JS, et
al. A gene for familial juvenile nephronophtysis maps to
chromosome 2p. Nat genet 1993;3:342-45.
- Rosenthal W, Seibold A, Antaramian A, et
al. Molecular identification of the gene responsible for
congenital nephrogenic diabetes insipidus. Nature
1992;359:233.
- Deen PMT, Verdijk MAJ, Knoers NVAM, et
al.Requirement of human renal water channel aquaporin-2 for
vasopressin-dependent concentration of urine. Science
1994;264:92.
- Fushimi K, Uchida S, Hara Y, Marumo F, Sasaki S.
Cloning and expression of atypical membrane water channel of rat
kidney collecting tubule. Nature 1993;361:549.
- Lloyd SE, Pearce SHS, Fisher SE, et al.
A common molecular basis from three inherited kidney stone
diseases. Nature 1996;379:445.
- Simon DB, Karet FE, Hamdan JM, DiPietro A,
Sanjad SA, Lifton RP. Bartter�s syndrome, hypocalcaemic alkalosis
with hypocalciuria is caused by mutations in the NA-K-2CL
cotransporter NKCC2. Nat Genet 1996;13:1S3-8
- Harden, PN, Geddes C, Rowe PA, et
al.Polymorphisms in angiotensin-converting enzyme gene and
progression of IgA nephropathy. Lancet 1995;345:1540.
- Oudit GY, et al.Loss of
angiotensin-converting enzyme 2 leads to the late development of
angiotensinII dependent glomerulosclerosis. Am J Pathol
2006;168:822-8.
- Janssen B, et al.Carnosine as a
protective factor in diabetic nephropathy: association with elucine
repeat of carnosinase gene CNDP1. Diabetes 2005;56:2325-32.
- Elles R. Molecular diagnosis of genetic
diseases. Humana Press. Totowa, New Jersey, 2000.
- Borst MH, Benigni A, Remuzzi, G. Primer:
strategies for identifying genes involved in renal disease. Nature
Clinical Practice Nephrology 2008;4:266-76.
|